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Systemic drugs are one of the most potent means for controlling beast cancer. Their ability to kill cancer cells often depends on the presence of appropriate physiological conditions, e.g., the uptake and retention of 5-fluorouracil (5-FU) may be influenced by pH. This opens the possibility of predicting which tumors will show best response by measuring pH a priori or modulating tumor physiology to optimize tumor selectivity. We have developed a novel class of non-invasive NMR pH indicators and propose a novel second generation of enhanced indicators to investigate breast tumor pH. We have now successfully synthesized our first trifluoromethyl pyridoxol pH indicator, which displays a narrow 19F NMR resonance and is sensitive to pH. This molecule has the advantage of three times the signal to noise of previous indicators.
It has been tested in blood and will be evaluated in breast tumors in the near future. We will also investigate the feasibility of manipulating pH in order to enhance breast tumor uptake. An exciting additional finding is that the NMR approach is potentially suitable for assaying additional tumor characteristics and we have invented a novel concept in testing for gene transfection.
Introduction
Systemic drags are one of the most potent means for controlling breast cancer. Their ability to kill cancer cells often depends, however, on the presence of appropriate physiological conditions. For instance, exciting recent results suggest that uptake and retention of 5-fluorouracil (5-FU) in tumors may be influenced by pH, in particular, the trans membrane pH gradient. This opens the possibility of predicting which tumors will show best response by measuring pH a priori or modulating tumor physiology to optimize tumor selectivity. We have developed a novel class of non-invasive NMR pH indicators and propose a novel second generation of enhanced indicators, which we will use to investigate breast tumor pH. Specifically, we will survey a series of diverse breast tumors in order to examine the specific correlation of 5-FU uptake versus pH gradient. In addition, we shall investigate the feasibility of manipulating pH in order to enhance breast tumor uptake.
We have three specific aims for this project:
Phase 1 Design, synthesis and evaluation of next generation molecules: Based on our experience with 6-fluoropyridoxamine (6-FPAM) [1, 2] , we have designed a second generation of enhanced pH indicator incorporating a trifiuoromethyl group. These will provide three times greater signal intensity, improving the precision, and accuracy, of pH measurements in vivo. We will synthesize and characterize this new generation of improved 19p NMR pH indicators.
Phase 2
Evaluation of a novel series of pH indicators in vivo: Test trifiuoromethyl pyridoxol in breast tumors in vivo. We believe the proposed pH indicators incorporating CF3 reporter groups will offer considerable advantages over our current pH indicator 6-FPAM. However, should they fail to meet expectations (e.g., due to toxicity or failure to cross cell membranes) then our current best reporter molecule (6-FPAM) will be used. These fluorine NMR pH indicators exhibit very strong NMR chemical shift response to changes in pH. They readily permeate cells providing simultaneous measurement of intra-and extracellular pH, and hence, the pH gradient.
Phase 3
Application of the new molecules to critical issues in breast cancer: We will compare the regulation of pH gradients in two human and two rat tumor sublines that exhibit diverse therapeutic response (viz. mammary adenocarcinoma 13672-NF and PAM-CTX sublines and human breast tumors with differing metastatic potential, p53 and Her 2-neu expression), Specific hypotheses to be tested include: a) that breast tumor pH may be measured accurately, and reproducibly, with useful temporal resolution using l^F jyjR-ty that CF3-pyridoxol will provide enhanced pH measurement in breast tumors, and c) that tumors exhibiting different therapeutic response exhibit significant differences in pH regulation. We believe this research will enhance the understanding of tumor pH dynamics, and promises a new prognostic tool to optimize therapy for individual breast tumors.
Body
While we continue to make progress towards the goals of this program, we have experienced some delays. In February this year, Dr. Pieter Otten, who had been recruited in Year 1 as the synthetic chemist moved to an exciting new position with Chembridge Pharmaceuticals in San Diego, CA. The training and research opportunities gained through his participation in this project were of considerable value to his securing the position, but it has caused a delay in our synthetic efforts. We have now recruited an excellent replacement synthetic chemist, Dr. Jianxin Yu (CV appended-item 1), who started in August and is making progress towards the synthetic targets. I have also recruited a second chemist, who will join the laboratory at the start of November. Dr. Wei-na Cui's (CV appended-item 2) primary tasks will be the NMR studies of tumor transmembrane pH and biodistribution and pharmacokinetics of chemotherapeutic drugs. The presence of two chemists in Year 3 will allow us to accelerate studies to compensate for delays. A further delay was caused by failure of both the 4.7 T and 400 MHz NMR systems at the Rogers NMR Center in May this year. This precluded any in vivo NMR investigations. Both systems are scheduled to be upgraded and functional again by January 2002, facilitating the originally planned investigations. In addition, we are able to use a 600 MHz instrument for interim tests.
Statement of Work
Phase 1 Design, synthesis and evaluation of enhanced ^F NMR pH indicators:
Task 1
Months 1-6: Recruit and train post-doctoral fellow in synthesis of fluorinated vitamin B6 analogs While we had recruited a chemist in year 1, he moved on to industry. We have now recruited an outstanding replacement organic synthetic chemist, Dr. Jianxin Yu (curriculum vitae appended; item 1). Dr. Yu has initiated syntheses and designed new synthetic strategies. He has refined synthetic approaches to improve yields and reaction efficiency and is becoming proficient in high field NMR to characterize the new molecules.
Task 2
Months 3-9 Synthesize CF3-pyridoxol Our first CF3-pyridoxol 19 F NMR pH indicator was synthesized in year 1, as proposed in the grant application. The final synthetic route was slightly modified. A draft manuscript describing the synthetic approach is appended (Item 3) and will be submitted to BioOrganic Medicinal Chemistry letters in the near future. Dr. Yu has proposed a new synthetic strategy to create di-CF3 pyridoxols (Appendix item 4).
Task 3 Months 6-12 Synthesize CF3-pyridoxol derivatives modified at 4, 5 and 2 position
Incorporation of an internal chemical shift reference standard can enhance utility of pH reporter molecules. In year 1 we synthesized a derivative of 6-fluoropyridoxol incorporating a 5-SCF3 group. However, this indicator tended to precipitate at neutral pH and exhibited very broad lines, which were of little use for NMR studies of pH. We proceeded to synthesize a second molecule incorporating a trifluoroacetamido group (NCOCF3) (Appendix 5). This produced narrow lines, but the spectrum is complicated by additional NMR resonances, which we attribute to a second molecular conformation (eis vs. trans.). While this indicator may not be ideal, it could be useful and we are testing it further Appendix item 6 shows titrations).
Task 4
Months 3-12 Characterize new pH indicators, e.g., 19 F NMR titrations, high resolution mass spectrometry, ^H, ^F and ^C NMR structural analysis We have now performed additional titration curves, e.g., on the trifluoroacetamido derivative (Appendix 5), which showed good pH sensitivity and useful pKa, but complexity due to isomers. Other materials are undergoing spectral analysis in preparation for publication. We have also identified an additional class of pH reporter molecule (fluoro nitro phenols), which show strong 19F NMR response to pH and may be useful in vivo (Appendix item 6).
Task 5
Months 6-12: Evaluate molecules in plasma and whole blood Initial molecules were tested in year 1 and further material will be evaluated as they are synthesized.
Task 6
Months 9-15: Scale up synthesis of most promising molecules CF 3 -pyridoxol was produced in 300 mg quantity. Other materials will be scaled up as needed.
Task 7
Months 9-18: Evaluate most promising molecules in perfused heart model To be undertaken, by Dr. Cui upon her arrival this year.
Task 8
Month 12: Prepare reports and manuscript. Report provided. Draft manuscripts appended.
Phase 2 Evaluation of optimal pH indicator in vivo:

Task 9
Month 9-18: Evaluate best molecule in breast tumor subline 13672NF (6 tumors) i:
Surgically create pedicles for tumor implantation ii: Implant tumors and allow to grow to 1 cm diameter iii: Examine pharmacodynamics of pH indicators in vivo; measure baseline pH; verify validity of measurements using 3 lp NMR and electrodes.
Tumors have been prepared. In vivo assessments will be undertaken by Dr. Cui, as soon as the new MRI systems are functional.
Reportable outcomes •Two draft manuscripts (Appendix items 3 and 5)
•Chemist trained for industry •We successfully competed for an NCI P20 In vivo Cancer Cellular and Molecular Imaging Center Planning grant. The concepts established under the auspices of this DOD BrCa IDEA award were a significant factor is making a successful application. In particular, the spin off technology, identifying gene reporter molecules could have far reaching influence on gene therapy. Further details of this grant and research program may be found on our new web site (http://cip.swmed.edu/ICMICA.
Conclusions
• CF3 analogues of F-pyridoxine pH indicators can be synthesized and, as predicted, show a sensitivity ~ 1.5 ppm. 19 F resonances are sufficiently narrow to allow useful NMR discrimination of pH. Signal to noise is dramatically improved by the presence of three identical "F" atoms as opposed to a single atom.
• Further experiments are required to modify cellular conditions is order to stimulate uptake of the new class of molecule into cells. This may involve synthesis of further derivatives, which are readily taken up, or manipulation of cellular environment.
• By analogy with the pH reporter molecules originally proposed in this work, we are able to assay gene expression using appropriate 19 
Design and Synthesis of Linkers constituted with Pentapeptides and Estrogen
Estrogen can also promote bone formation. There is "promissive effect" between peptides and steroids in linkers constituted with peptides and steroids. Therefore we designed and prepared a series of compounds, which are linkers of pentapeptides and estone or estradiol.
Effect of Pentapeptides and Linkers on Osteoporosis and the studies of their SAR
In order to evaluate the effect of above-mentioned compounds on osteoporosis, predinisone was used to induce osteoporosis, at the same time estone and estradiol were regarded as positive controls. Seven indexes were measured, including weight of ratsd ry weight of femursas h weight of femursca lcium content of femurs phosphorous content of femurss erum concentration of calciumse rum concentration of alkaline phosphatase. The results indicated that some of the compounds could prevent bone loss, showing potential activity. The studies of SAR showed that linkers revealed predominant pharmacological action than peptides and estrogen. 
Draft manuscript for submssion to Bioorganic Medicinal Chemistry letters 6-CF3POL
The introduction of a trifluoromethyl group at an aromatic ring can be achieved by a substitution reaction on an aryl iodide with trifluoromethyl copper ("CuCF 3 ") [7] . Urata [8] described a convenient method for the in situ generation of Q1CF3 by a metathesis reaction of commercially available Et3SiCF3 with Cul in the presence of an aryl iodide which serves as the substrate in the trifluoromethylation reaction. For the synthesis of 6-(trifluoromethyl)pyridoxine (18), we required access to 6-iodopyridoxine (19) and protection of its alcohol groups. The threestep halogenation of pyridoxine (2)-via 6-aminopyridoxine (4), followed by a Sandmeyer reaction -has been very successful for the synthesis of our 19 F NMR pH indicator 6-fluoropyridoxine (1) [1, 2, 9, 10 ]. We decided, however, to attempt the direct iodination of pyridoxine (2) using a procedure previously described for the iodination of 3-hydroxypyridine in aqueous base [11] . The reaction of pyridoxine (2) with iodine was carried out in 10% K2CO3 generating the pyridoxine anion, which is the actual reactive species. Acidification of the reaction mixture resulted in the precipitation of 6-iodopyridoxine. 19 could be obtained pure in a yield of 68% by filtration. Attempts to protect all three hydroxy groups of 19 at once as their respective benzyl ethers (NaH, benzyl chloride, DMF) failed and led to unidentifiable product mixtures. Instead, a two step approach was used. Firstly, the more acidic phenolic hydroxy group was protected as its benzyl ether by using milder basic reaction conditions: K2CO3 in warm DMF in the presence of benzyl chloride, which afforded benzyl ether 20 in a modest 31% yield. Next, the two remaining hydroxy groups were protected together in the form of acetone acetal 21. Acetal 21 was obtained in 68% yield by the reaction of 20 in acetone in the presence of a catalytic amount ofp-toluenesulfonic acid followed by Chromatographie work-up.
We were gratified to see that Urata's trifluoromethylation methodology for phenyl iodides could be extended to a more sterically hindered iodopyridine ring such as our protected iodopyridoxine 21. Thus, reaction of 21 in a mixture of DMF and NMP (v/v:l/l) in the presence of Cul, Et 3 SiCF 3 (b.p. 41 °C), and KF in a sealed tube at 80 °C led to complete conversion of 21 and gave protected 6-(trifluoromethyl)pyridoxine 22 in a yield of 75% after purification by flash chromatography. Subsequent removal of the acetal protection of the aliphatic hydroxy groups was carried out in a mixture of dioxane and IM HC1 at 80 °C. Benzylated (trifluoromethyl)pyridoxine 23 precipitated upon removal of the dioxane from the reaction mixture and was isolated in a yield of 85 % after filtration. The synthesis of the desired 6-(trifluoromethyl)pyridoxine (18) was finalized by deprotection of the phenolic hydroxy group by hydrogenolysis of the benzyl ether 23, which proceeded in near quantitative yield. 
21
Titrations
The 19 F NMR signal of 6-CF3POL in water shows one sharp line. Using CF 3 COONa as a reference, the chemical shift moves downfield from 15.16 ppm (at pH = 2.18) to 16.74 ppm (at pH = 11.08) upon increasing pH. Thus, the chemical shift sensitivity of 6-CF3POL is a factor 6 less than 6-FPOL. This observation can be readily explained by the fact that in 6-CF3POL the three reporting fluorine atoms are not in direct communication through resonance with the sensor: the phenolic OH group. The pK a of 6-CF3POL was determined at 6.7 compared to 8.2 for 6-FPOL. Apparently, the stronger electron-withdrawing nature of the CF3 group causes this marked increase in acidity, which makes 6-CF3POL a better probe for physiological measurements in more acidic tumor tissue. No significant line broadening of the 9 F resonance was observed at or around the pK a value of 6-CF3POL. In our opinion, this means that despite the reduced chemical shift range, 6-CF3POL will be useful as a sensitive NMR pH indicator.
In fresh rabbit blood, at 22 °C, 6-CF3POL shows only one resonance after incubation at 37 °C for 4 hours (2 mg of CF3POL in 0.5 ml of blood). This observation clearly indicated that no significant amounts, if any at all, of 6-CF3POL accumulated in the available red blood cells to allow the detection of an intracellular signal. Raising the NMR probe temperature to 37 °C did not result in the appearance of an additional, intracellular, signal. This is in sharp contrast to our 15 observations for 6-FPOL and its amino derivative 6-FPAM (pK a = 7.05) which both report an intracellular 19 F NMR signal within minutes after mixing with fresh blood. In this particular blood sample, CF3POL displayed a resonance at 16.49 ppm, which corresponds with an extracellular pH of 7.47 after applying the Henderson-Hasselbach equation. The pH of the sample was determined at 7.39 by a pH electrode. At this point it is not clear whether 6-CF3POL does not penetrate the cell membrane at all, or whether it is rapidly expelled again from the cell by a transporter after entering the cell by either diffusion and/or active transport. Methods 6-Iodopyridoxine (). To a suspension of 4.25 g (25 mmol) pyridoxine in 75 ml water was added 6.9 g (47 mmol) K 2 C0 3 resulting in complete dissolution of all solid material. Subsequently, 6.3 g (25 mmol) iodine was added in one portion followed by stirring for 1 h at room temperature. To the dark brown reaction mixture, 400 mg Na 2 S0 3 was added resulting in a yellow clear solution. The reaction mixture was subsequently quenched with concentrated HC1 to a pH of 3 and the precipitate was isolated by filtration over a Büchner filter and dried in vacuo over sodium hydroxide to give 4.98 g (68 %) of a yellow powder. 'H NMR (dmso-d 6 ) 8 2.30 (s, 3H), 4.55 (d, J = 6 Hz, 2H), 4.79 (s, 2H), 5.07 (t, J = 6 Hz, 1H), 5.8 (br, 1H), 9.5 (br, 1H).
6-Iodo-3-0-benzylpyridoxine (). To a solution of 9 g 6-iodopyridoxine (31 mmol) in 30 ml dry DMF under argon were added 18 g K 2 C0 3 (123 mmol) and 12 ml benzylchloride (104 mmol). The reaction mixture was stirred at 60 °C overnight, allowed to cool to room temperature, and filtered over a Büchner filter. The filtrate was poured into 200 ml water and extracted three times with 200 ml EtOAc. The combined organic layers were dried on MgS0 4 , filtered, and evaporation of the solvent in vacuo gave a dark solid, which was triturated with 50 ml diethyl ether. Filtration over a glass filter and drying in vacuo over sodium hydroxide gave 4. 6-Iodo-3-0-benzyl-a 4 ,a 5 -0-isopropylidenepyridoxine (). To a solution of 4.2 g (11 mmol) 6-iodo-3-O-benzylpyridoxine ( ) in 60 ml acetone was added 1.2 g /7-toluenesulfonic acid. The reaction mixture was stirred at room temperature for two days after which another 50 ml of acetone and 1 g of/»-toluenesulfonic acid were added, followed by an additional stirring for 16h. The reaction mixture was neutralized by the addition of 50 ml water and 3 g K2CO3. The acetone was removed in vacuo and the remaining aqueous layer was extracted three times with 150 ml EtOAc. The combined organic layers were dried on MgS0 4 , filtered, and evaporation of the solvent in vacuo gave a dark oil which was further purified by flash chromatography (eluent: 10% EtOAc in hexane) to give 3. 
3-0-benzyl-a
4 ,a 5 -0-isopropylidene-6-(trifluoromethyl)pyridoxine (). To a solution of 760 mg (1.8 mmol) 6-Iodo-3-0-benzyl-a 4 ,a 5 -0-isopropylidenepyridoxine ( ) in a mixture of 2 ml DMF and 2 ml NMP in a 15 ml glass pressure tube were added 510 mg (2.7 mmol) Cul and 125 mg (2 mmol) KF. The well-stirred solution was kept under an argon flow for 30 min followed by the addition of 500 ul Et 3 SiCF 3 (2.7 mmol) and the tube was sealed. The mixture was stirred at 80 °C for 16 h and allowed to cool to room temperature. The clear, dark brown reaction mixture was poured into 100 ml water and the resulting white suspension was extracted three times with 200 ml diethyl ether. The combined organic layers were washed three times with 100 ml water, dried on MgS04, filtered and evaporation of the solvent in vacuo gave a dark oil which was purified by flash chromatography (eluent: 10% EtOAc in hexane) to give 496 mg (75 %) of a colorless viscous oil. *H NMR (CDC1 3 3-0-benzyl-6-(trifluoromethyl)pyridoxine ( ). To a solution of 1.5 g (4.0 mmol) 3-0-benzyla 4 ,a 5 -0-isopropylidene-6-(trifluoromethyl)pyridoxine () in 10 ml 1,4-dioxane was added 5 ml 1 M HC1. The turbid mixture was heated to 80°C, eventually became clear, and stirring was continued for 4 h at this temperature. TLC (eluent: 25% EtOAc in hexane) indicated that all starting material had been consumed. After the reaction mixture was allowed to cool to room temperature, all volatile materials were removed in vacuo which resulted in the formation of a white precipitate. The crude product was evaporated to dryness, suspended in 10 ml water and filtered. The residue was dried in vacuo on NaOH to give 1.1 g (85 %) of a white powder. *H NMR (dmso-d 6 ) 6 2.49 (s, 3H), 4.72 (s, 4H), 5.00 (s, 2H), 7.40-7.45 (m, 3H), 7.52-7.54 (m, 2H).
6-(trifluoromethyI)pyridoxine (6-CF3POL, )
. To a suspension of 1.0 g (3.1 mmol) of 3-0-benzyl-6-(trifluoromethyl)pyridoxine () in 100 ml ethanol was added 500 mg of 5% Pd on C. The mixture was hydrogenolyzed for 16h under 25 psi after which TLC (eluent: 50% EtOAc in hexane) indicated complete consumption of the starting material and the formation of one single product. The reaction mixture was filtered over Celite and the solvent was evaporated in vacuo to give 731 mg (99 %) of an off-white solid.
! H NMR (dmso- 
